Objective: The primary objective of this study was to determine whether Transcranial Magnetic Stimulation (TMS) -evoked Ipsilateral Silent Period (ISP) latency, which reflects trans-callosal, inter-hemispheric inhibition, correlates with presence and severity of Attention Deficit/Hyperactivity Disorder (ADHD) in childhood as well with commonly observed delays in motor control. Background Children with ADHD often fail to meet age-norms in development of motor control, particularly timed repetitive and sequential movements, motor overflow, and balance. The neural substrate of this motor delay and particularly motor overflow may include impaired or delayed mechanisms of inter-hemispheric, inhibitory signaling which contribute to both motor and behavioral symptoms. Design/Methods: Case-Control Study. Behavioral ratings, motor skills, and motor cortex physiology were evaluated in 50 ADHD (mean age 10.9 years, 29 male) and 64 typically developing (TD) (mean age 11.1 years, 33 male) children, all right-handed, ages 8-12 years. Motor skills were evaluated with the Physical and Neurological Examination for Soft Signs (PANESS). ISP and other physiological measures were obtained using TMS in left motor cortex. Results: ISP was successfully elicited in 54 (47%) children (23 ADHD, 31 TD, p = NS). Children in whom ISP was unobtainable were younger (p=.03) and had higher resting and active motor depolarization thresholds, but did not differ in other clinical, intellectual, or motor symptoms. In ADHD children, mean ISP latency was increased by 5 msec (12%) (p=.007). Longer ISP latencies (slower trans-hemispheric signaling) correlated with more severe ADHD symptom scores (r=.36, p = .009), particularly hyperactivity (r = .37, p = .007) as well as with worse motor overflow ratings on the PANESS (r = .27, p = .05) and diminished intra-hemispheric, TMS-evoked Short Interval Cortical Inhibition (SICI) (r = .34, p = .02). Conclusions: Slower trans-hemispheric inhibitory signaling reflects both behavioral and motor control problems in children with ADHD. Supported by: R01 MH078160. Disclosure: Dr. Gilbert has received personal compensation in an editorial capacity for Pediatrics Review and Education Program R11. Dr. Gilbert has received research support from Psyadon Pharmaceuticals and Otsuka Pharmaceuticals. Dr. Wu has received research support from Psyadon Pharmaceuticals, Otsuka Pharmaceutical and Genzyme Corporation. Dr. Shahana has nothing to disclose. Dr. Huddleston has nothing to disclose. Dr. Shiels has nothing to disclose. Dr. Mostofsky has nothing to disclose.